| Nov 7 |
LifeMD Non-GAAP EPS of $0.14 beats by $0.07, revenue of $53.4M misses by $0.4M
|
| Nov 7 |
LifeMD Reports Third Quarter 2024 Results
|
| Nov 6 |
LifeMD Q3 2024 Earnings Preview
|
| Nov 6 |
LifeMD® Launches Affiliated Pharmacy to Drive End-to-End Patient Care and Operational Efficiency
|
| Oct 24 |
LifeMD launches TestoRx, direct to consumer testosterone replacement therapy
|
| Oct 24 |
LifeMD® to Report Third Quarter 2024 Financial Results on November 7
|
| Oct 23 |
LifeMD® Launches TestoRx, a New Rex MD® Direct-to-Consumer Testosterone Replacement Therapy Telehealth Offering
|
| Oct 12 |
LifeMD, Inc.'s (NASDAQ:LFMD) top owners are retail investors with 45% stake, while 38% is held by institutions
|
| Sep 24 |
LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
|
| Sep 23 |
LifeMD: Are The Commons Too Cheap?
|
